Mindbio Therapeutics Corp.
0.05
EUR
+0.00
(+0.42%)
ISIN
CA60256C2076
CUSIP
60256C207
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Quarterly Revenue
AUD
•
in mil. unless spec.Quarterly Earnings Per Share
AUD
•
in mil. unless spec.Quarterly Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Justin Adam Hanka
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Vancouver Canada
- IPO Date
- May 5, 2023
- Website
- mindbiotherapeutics.com
- Similar Companies
- Business
- MindBio Therapeutics Corp. is a clinical-stage biotechnology company focused on the research, development, and commercialization of novel sub-hallucinogenic microdosing psychedelic medicines and proprietary treatment regimens for the treatment of debilitating mental health and central nervous system disorders. Headquartered in Vancouver, Canada, with operational and research activities in Melbourne, Australia and Auckland, New Zealand, the company was established in 2021 and completed its public listing on the Canadian Securities Exchange in 2023. MindBio Therapeutics specializes in developing pharmaceutical-grade take-home microdosing protocols paired with proprietary digital health technologies to facilitate scalable, accessible psychiatric care. The company's core product and development pipeline comprises: MB22001, a proprietary sublingual microdose formulation of lysergic acid diethylamide (LSD) designed for safe, self-administered at-home treatment of Major Depressive Disorder (MDD), cancer-related distress, and Premenstrual Dysphoric Disorder (PMDD); MB22002, an investigational proprietary formulation of microdosed psilocybin targeted for chronic neuropsychiatric indications; proprietary microdosing treatment protocols, engineered to deliver neuroplasticity and antidepressant benefits without inducing hallucinogenic effects or requiring in-clinic supervision; and integrated digital therapeutic systems, encompassing remote patient biometric monitoring, sleep tracking analytics, and digital biomarker tools to measure treatment efficacy and safety in real-world outpatient settings. In recent developments, MindBio Therapeutics completed a successful spin-out transaction from Blackhawk Growth Corp. to establish itself as an independent public entity listed on the Canadian Securities Exchange under the ticker MBIO, alongside dual-quotations on the OTCQB Venture Market and the Frankfurt Stock Exchange. Operationally, the company achieved significant clinical milestones by reporting positive top-line results from its Phase 2a clinical trial evaluating MB22001 in patients with Major Depressive Disorder, which demonstrated statistically significant reductions in depressive symptoms and enhancements in sleep quality without perceptual distortions. Building on these clinical outcomes, MindBio Therapeutics advanced into Phase 2b randomized, double-blind, placebo-controlled trials for MB22001 across depression and cancer-distress indications, secured expanded regulatory and ethics approvals for take-home psychedelic dosing, and broadened its global intellectual property portfolio covering novel chemical formulations, dosing regimens, and digital monitoring systems.